Evaxion biotech announces clinical collaboration to evaluate lead product candidate with keytruda® (pembrolizumab) in patients with melanoma

Copenhagen, denmark, oct. 25, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today that it has entered into a clinical trial collaboration and supply agreement with subsidiaries of merck & co., inc., kenilworth, nj, usa (known as msd outside the united states and canada), to evaluate the combination of evaxion's cancer immunotherapy evx-01 with msd's anti-pd-1 therapy keytruda® (pembrolizumab) in a new phase 2b study.
EVAX Ratings Summary
EVAX Quant Ranking